Not Yet RecruitingNot Applicable

Royal Jelly Supplementation in Unexplained Male Infertility

80 participantsStarted 2026-02-01

Plain-language summary

This randomized, double-blind, placebo-controlled clinical trial investigates the effects of oral Royal Jelly supplementation on sperm DNA fragmentation and pregnancy rates in couples with unexplained infertility. While routine semen analysis appears normal (normozoospermia) in these patients, underlying Sperm DNA Fragmentation (SDF) and oxidative stress are believed to contribute to reproductive failure. Participants will be randomized to receive either 750 mg of lyophilized Royal Jelly or a placebo daily for a period of 3 months (90 days). The study aims to evaluate whether the antioxidant properties of Royal Jelly can improve sperm chromatin integrity, reduce oxidative stress markers, and increase spontaneous pregnancy rates compared to the control group

Who can participate

Age range18 Years – 45 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men aged 18-45 years. History of infertility for at least 1 year despite unprotected intercourse. Diagnosis of unexplained infertility with Normozoospermia according to WHO 2021 (6th Ed.) criteria: Concentration ≥ 16 million/mL Total Motility ≥ 42% Progressive Motility ≥ 30% Normal Morphology (Kruger) ≥ 4% Female partner with normal gynecological evaluation (regular ovulation, normal ovarian reserve, and proven tubal patency via HSG). Normal serum hormone levels (Testosterone, FSH, LH) Exclusion Criteria: * Any abnormality in spermiogram (Oligo-, Asteno-, or Teratozoospermia). Presence of clinical varicocele. Leukocytospermia (\>1 million/mL) or active infection. History of smoking (\>5 cigarettes/day) or BMI \> 30 kg/m². Use of any antioxidant supplementation within the last 3 months.

What they're measuring

Change in Sperm DNA Fragmentation Index (SDF)

Timeframe: Baseline (Day 0) and Post-treatment (Day 90)

Spontaneous Pregnancy Rate

Timeframe: Up to 3 months (90 days)

Trial details

NCT IDNCT07337265

SponsorMedipol University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-01

Contact for this trial

Ali İhsan Memmi

+90 537 922 0997 alimemmi@gmail.com